Candida auris: A Comprehensive Analysis of Clinical Trials

Authors

  • Rachel Elizabeth Wilkins Oklahoma State University College of Osteopathic Medicine at Cherokee Nation, Office of Medical Student Research, Tahlequah, Oklahoma
  • Sarah Wilkinson Oklahoma State University College of Osteopathic Center for Health Sciences, Office of Medical Student Research, Tulsa, Oklahoma
  • Eugenio Hernandez, Pharm D. Oklahoma State University Medical Center, Department of Pharmacy, Tulsa, Oklahoma
  • Benjamin Greiner, D.O., M.P.H. Saint Francis Health System, Warren Clinic Internal Medicine, Tulsa, Oklahoma
  • Micah Hartwell, Ph.D. Oklahoma State University College of Osteopathic Medicine at Cherokee Nation, Office of Medical Student Research, Tahlequah, Oklahoma and Oklahoma State University Center for Health Sciences, Department of Psychiatry and Behavioral Sciences, Tulsa, Oklahoma

Abstract

Abstract

Background: Candida auris (C. auris) was isolated in 2009 and has continued to increase in prevalence. Most strains exhibit multidrug resistance to primary antifungal treatments, increasing the difficulty of treatment by healthcare professionals. The World Health Organization designated C. auris on the fungal priority pathogen list and urges further research of treatment regimens to enhance scientific understanding and improve patient outcomes. Our goal was to analyze pertinent clinical trials regarding treatment of C. auris infections.

Methods: We analyzed the National Library of Medicine’s Clinical Trials (Clinicaltrials.gov; CTG) with a secondary search through MEDLINE (PubMed.gov). The search string used for CTG included the terms ‘Candida auris’ or ‘Invasive candidiasis” with ‘C. auris’ in the “other” field. Our search of PubMed used the following search string: (((clinical trial) AND (phase)) AND (candida auris).

Results: Few clinical trials have been started regarding C. auris and even fewer have published results with effective treatment modalities. Our search of CTG resulted in 7 unique trials with an additional 1 found using PubMed. Of these trials, 5 were interventional studies that used one of the following medications: fosmanogepix, oral ibrexafungerp (SCY-078), rezafungin, caspofungin, fluconazole, and intranasal 10% povidone-iodine. Of these, 2 trials have published results with anti-fungal treatments- NCT04148287 and NCT03667690.

Conclusion: Publishing the results of clinical trials promptly, increasing the amount of therapeutic research, and continuing further education of healthcare professionals and patients are essential in the development of an effective and safe cure for C. auris infections.

Downloads

Published

2024-12-12

Issue

Section

Medical